



## Emerging Paradigms in Insulin Resistance

Guest Editor:

**Dr. Susan J. Burke**

Pennington Biomedical Research  
Center, Baton Rouge, LA, USA

Deadline for manuscript  
submissions:

**closed (30 November 2021)**

### Message from the Guest Editor

Insulin resistance is defined as defective insulin action in its target tissues. There are many discrete routes to the onset of peripheral insulin resistance, e.g., obesity, chronic glucocorticoid excess, lipodystrophy, etc.; therefore, much remains to be determined regarding the underlying pathology of insulin resistance and tissue specific mechanisms.

This Special Issue of *Biomedicines* is entitled “Emerging Paradigms in Insulin Resistance”. The topics covered in the Special Issue include but are not limited to original research articles that identify novel pathways and factors involved in the development of insulin resistance, emerging technological advances or tools in the study of insulin resistance, and novel genetic models developed to study insulin resistance and associated metabolic pathologies. We also invite the submission of review articles that provide a comprehensive overview of recent innovative advances in studying insulin resistance and its consequent metabolic alterations.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)